0% vs. -21.7%), in comparison with those in the MVPA <250 min/wk group. This attenuation was likely independent of the detectable weight reduction. MVPA for ≥250 GS 1101 min/wk led to a significant decrease in the abdominal visceral fat area severity (−38.6% vs. −23.4%), levels of ferritin (−11.8% vs. +0.1%), and lipid peroxidation (−15.6% vs. −2.8%), and a significant increase in the adiponectin (+17.9% vs. +4.6%) and HDL-C (4.0% vs. 9.6%) levels. In association with these changes, the gene expression levels of sterol regulatory element-binding

protein 1c and carnitine palmitoyltrans-ferase I in leukocytes also significantly decreased (−5.6% vs. +2.4%) and increased (+4.3% vs. −2.7%), respectively. However, the parameters in liver function test (AST; −19.1% vs. −14.2%, ALT -34.4 vs. −30.9% and γGT-44.2% vs.−45.5%) did not differ significantly between the groups. Conclusions: MVPA for ≥250 min/wk

induces a potent improvement in NAFLD pathophysiology in obese men. It is likely that the benefits are Palbociclib in vivo acquired through reducing inflammation and oxidative stress levels and altering fatty acid metabolism. Disclosures: The following people have nothing to disclose: Sechang Oh, Takashi Shida, Rina So, Takehiko Tsujimoto, Kiyoji Tanaka, Junichi Shoda Background. FibroMax is a panel of blood tests assessing the severity of fibrosis (FibroTest), steatosis (SteatoTest), and necro-inflammatory activity (ActiTest and NashTest). In contrast with viral hepatitis (specific scoring system METAVIR, extensive validations), blood tests have been less validated in NAFLD patients (pts). Recently (Hepatology 2014), SAF score (S=Steatosis; A=Activity; F=Fibrosis) and FLIP algorithm have permitted to categorize liver lesions in NAFLD and to identify histologically severe forms (HSF, as A≥3 and/or F≥3). The aim was to validate FibroMax using SAF/FLIP in NAFLD pts. Methods. Pts from 2 NAFLD cohorts (consecutive metabolic risk factors’ pts, tertiary center, cohort 1) and multicenter NASH therapeutic

trial (cohort 2), were included if interpretable biopsies have been centrally and Resveratrol blindly reassessed with SAF/ FLIP algorithm, and contemporaneous FibroMax prospectively assessed according to analytical recommendations, applicability algorithms and previously validated cutoffs. For categorical scores area under the AUC (AUROCs) were assessed with Obuchowski measures (weighted AUROCs between all combinations of SAF scores preventing spectrum effect), were performed per protocol (PP) and in intention to diagnose (ITD). Results. 207 pts were included; 60% male, median age 54yr, BMI 29, biopsy length 25mm; according to SAF/FLIP: 16(8%) were classified as not-NAFLD (steatosis<5%), 64 (31%) as Ste-atosis without NASH and 127 (61%) as NASH. Performances of blood tests were highly significant (Table; all P<0.001) for predicting SAF scores and FLIP categories.